Table of Contents
Executive Summary
- Introduction
- Categorizing and valuing innovation
- Region and therapy area specific considerations
- Pricing challenges for recently launched innovative therapies
- Upcoming launches of new innovative therapies
Chapter 1 Introduction
- Summary
- Introduction
- Supply-side factors
- Complexity and costs
- Market size
- Competition
- Demand-side factors
- Budget
- Unmet need
- Competition
- Valuing innovation
Chapter 2 Categorizing and valuing innovation
- Summary
- Introduction
- Categories of innovations
- New market innovations
- Redefining the category innovations
- Second generation innovations
- Incremental therapeutic innovations
- Incremental formulation innovations
- Innovative market access strategies
- Orphan drugs
- Risk-sharing
Chapter 3 Region and therapy area specific considerations
- Summary
- Introduction
- Approaches to market access in major markets
- USA
- Japan
- France
- Germany
- Italy
- Spain
- UK
- Therapy area markets for innovative therapies
- Oncology
- HIV
- Autoimmune diseases
- Diabetes
- Others
Chapter 4 Pricing challenges of recently launched innovative therapies
- Summary
- Introduction
- New market innovations
- Gardasil (human papilloma virus vaccine): changing the treatment algorithm
- Lysosomal storage diseases: pricing versus patient weight
- Redefining the category innovations
- Chantix (varenicline): redefining a therapeutic category
- Nexavar (sorafenib) versus Sutent (sunitinib): meeting an unmet need
- Second generation innovations
- Lyrica (pregabalin): a new, improved neuropathic pain drug
- Macugen vs Lucentis vs Avastin : premium pricing against off-label use
- Incremental therapeutic innovations
- Byetta vs Januvia: changing the treatment paradigm for type 2 diabetes
- Prezista vs Fuzeon: premium pricing in HIV/AIDS
- Incremental formulation innovations
- Abraxane (paclitaxel): pricing incremental convenience
- Vivitrol: market access vs premium pricing
Chapter 5 Upcoming launches of new innovative therapies
- Summary
- Introduction
- New market innovations
- Lupuzor (IPP-201101) - ImmuPharma
- Sinunase - Accentia
- Redefining the category innovations
- Bapineuzumab - Elan/Wyeth
- Multikine - CelSci
- Second generation innovations
- Arzoxifene - Eli Lilly
- Cordaptive (niacin ER/laropiprant) - Merck
- Incremental therapeutic innovations
- Naproxcinod - NicOx
- RhuDex - MediGene
- Incremental formulation innovations
- Denosumab - Amgen
- Xarelto (rivaroxaban) - Bayer/J&J
- Chapter 6 Appendix
- Research sources
- Pricing data
List of Figures
- Figure 1.1: Supply and demand factors impacting market access for
innovative therapies
- Figure 2.2: Innovative drug categories by level of innovation and ease of
market access
- Figure 3.3: Source of prescription drug expenditures in the US, 2005-2006
- Figure 3.4: Italian categorization for innovative new therapies
- Figure 4.5: Gardasil global sales, 2006-07 ($m)
- Figure 4.6: Selected lysosomal storage disease drugs global sales, 2006-07
- Figure 4.7: Selected lysosomal storage disease drugs pricing in the UK and
US, 2008
- Figure 4.8: Smoking cessation drugs global sales, 2006-07
- Figure 4.9: Smoking cessation drugs pricing in the UK and US, 2008
- Figure 4.10: Nexavar and Sutent global sales, 2006-07
- Figure 4.11: Nexavar and Sutent pricing in the UK and US, 2008
- Figure 4.12: Selected neuropathic pain drugs global sales, 2006-07
- Figure 4.13: Selected neuropathic pain drugs pricing in the UK and US, 2008
- Figure 4.14: Age-related macular degeneration drugs global sales, 2006-07
- Figure 4.15: Age-related macular degeneration drugs pricing in the UK and
US, 2008
- Figure 4.16: Selected type 2 diabetes drugs global sales, 2006-07
- Figure 4.17: Selected type 2 diabetes drugs pricing in the UK and US, 2008
- Figure 4.18: Selected HIV/AIDS drugs global sales, 2006-07
- Figure 4.19: Selected HIV/AIDS drugs pricing in the UK and US, 2008
- Figure 4.20: Taxane drugs global sales, 2006-07
- Figure 4.21: Taxane drugs pricing in the US, 2008
- Figure 4.22: Alcohol dependency drugs global sales, 2006-07
- Figure 4.23: Alcohol dependency drugs pricing in the US, 2008
List of Tables
- Table 3.1: Classification for price premium (Japanese healthcare system)
- Table 4.2: Gardasil pricing in the UK and US, 2008
- Table 4.3: Selected lysosomal storage disease drugs pricing in the UK and
US, 2008
- Table 4.4: Smoking cessation drugs pricing in the UK and US, 2008
- Table 4.5: Nexavar and Sutent pricing in the UK and US, 2008
- Table 4.6: Selected neuropathic pain drugs pricing in the UK and US, 2008
- Table 4.7: Age-related macular degeneration drugs pricing in the UK and
US, 2008
- Table 4.8: Selected type 2 diabetes drugs pricing in the UK and US, 2008
- Table 4.9: Selected HIV/AIDS drugs pricing in the UK and US, 2008
- Table 4.10: Taxane drugs pricing in the UK and US, 2008
- Table 4.11: Alcohol dependency drugs pricing in the UK and US, 2008
- Table 5.12: Selected innovative therapies currently in late stage
development
- Table 6.13: Key UK and US pricing data for leading case studies, 2008
- Table 6.13: Key UK and US pricing data for leading case studies, 2008
(continued)
|
Related Report
|
View Cart
